
France Diabetes Drugs and Devices Market Growth, Size, Trends, Demand and Future Outlook
France Diabetes Drugs and Devices Market Size- By Drug, By Device- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
Published: Jun-2024 | Report ID: MEDE2434 | Pages: 1 - 110 | Formats*: |
Category : Medical Devices |
- November 2023: Novo Nordisk announced an investment of more than 16 billion Danish kroner (2.26 billion USD) beginning in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio in serious chronic diseases including diabetes. The investment will greatly improve the manufacturing site's capacity by adding aseptic and completed production processes, as well as extending the current Quality Control Laboratory.
- November 2023: ViCentra, Diabeloop, and Dexcom will launch a closed-loop diabetes system in Europe in 2024 to assist persons with Type 1 diabetes in better managing their disease.


Report Metric | Details |
Market size available for years | 2020-2033 |
Base year considered | 2023 |
Forecast period | 2024-2033 |
Segments covered | By Drug, By Device |
Regions covered | Eastern, Western, Northern, Southern |
Companies Covered | Novo Nordisk, Sanofi, Eli Lilly, Biocon, Medtronic, Ypsomed, Becton Dickinson. |
- Clinicians (Endocrinologists, Diabetologists, General Practitioners)
- Diabetes Patients and Caregivers
- Government Health Agencies and Regulators
- Hospitals and Healthcare Facilities
- Insurance Providers (Health Insurance Companies)
- Medical Device Manufacturers
- Pharmaceutical Companies
- Pharmacies and Retailers
- Research Institutions and Academia
- Support Organizations (Diabetes Associations, Patient Advocacy Groups)
By Drug: |
|
By Device: |
|
- France Diabetes Drugs and Devices Market Size (FY’2024-FY’2033)
- Overview of France Diabetes Drugs and Devices Market
- Segmentation of France Diabetes Drugs and Devices Market By Drug (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulin)
- Segmentation of France Diabetes Drugs and Devices Market By Device (Insulin Pumps, Insulin Pens, Insulin Syringes, Insulin Jet Injectors)
- Statistical Snap of France Diabetes Drugs and Devices Market
- Expansion Analysis of France Diabetes Drugs and Devices Market
- Problems and Obstacles in France Diabetes Drugs and Devices Market
- Competitive Landscape in the France Diabetes Drugs and Devices Market
- Impact of COVID-19 and Demonetization on France Diabetes Drugs and Devices Market
- Details on Current Investment in France Diabetes Drugs and Devices Market
- Competitive Analysis of France Diabetes Drugs and Devices Market
- Prominent Players in the France Diabetes Drugs and Devices Market
- SWOT Analysis of France Diabetes Drugs and Devices Market
- France Diabetes Drugs and Devices Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1.1. Scope of the report1.2. Market segment analysis
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
4.2. COVID-19 Impacts of the France Diabetes Drugs and Devices Market
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6.1. France Diabetes Drugs and Devices Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in France Diabetes Drugs and Devices Market
7.1. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Drug, 2020-20267.2. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Drug, 2027-20337.3. Basal or Long-acting Insulins
7.3.1. Lantus (Insulin Glargine)7.3.2. Levemir (Insulin Detemir)7.3.3. Toujeo (Insulin Glargine)7.3.4. Tresiba (Insulin Degludec)7.3.5. Basaglar (Insulin Glargine)
7.4. Bolus or Fast-acting Insulins
7.4.1. NovoRapid/Novolog (Insulin aspart)7.4.2. Humalog (Insulin lispro)7.4.3. Apidra (Insulin glulisine)7.4.4. FIASP (Insulin aspart)7.4.5. Admelog (Insulin lispro Sanofi)
7.5. Traditional Human Insulins
7.5.1. Novolin/Mixtard/Actrapid/Insulatard7.5.2. Humulin7.5.3. Insuman
7.6. Combination Insulins
7.6.1. NovoMix (Biphasic Insulin aspart)7.6.2. Ryzodeg (Insulin degludec and Insulin aspart)7.6.3. Xultophy (Insulin degludec and Liraglutide)7.6.4. Soliqua/Suliqua (Insulin glargine and Lixisenatide)
7.7. Biosimilar Insulins
7.7.1. Insulin Glargine Biosimilars7.7.2. Human Insulin Biosimilars
8.1. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Device, 2020-20268.2. France Diabetes Drugs and Devices Market Size, Share and Forecast, By Device, 2027-20338.3. Insulin Pumps
8.3.1. Insulin Pump Devices8.3.2. Insulin Pump Reservoirs8.3.3. Insulin Infusion sets
8.4. Insulin Pens
8.4.1. Cartridges in reusable pens8.4.2. Disposable insulin pens
8.5. Insulin Syringes8.6. Insulin Jet Injectors
9.1. France Diabetes Drugs and Devices Market Size and Market Share
10.1. France Diabetes Drugs and Devices Market Size and Market Share By Region (2020-2026)10.2. France Diabetes Drugs and Devices Market Size and Market Share By Region (2027-2033)10.3. Eastern10.4. Western10.5. Northern10.6. Southern
11.1. Novo Nordisk
11.1.1. Company details11.1.2. Financial outlook11.1.3. Product summary11.1.4. Recent developments
11.2. Sanofi
11.2.1. Company details11.2.2. Financial outlook11.2.3. Product summary11.2.4. Recent developments
11.3. Eli Lilly
11.3.1. Company details11.3.2. Financial outlook11.3.3. Product summary11.3.4. Recent developments
11.4. Biocon
11.4.1. Company details11.4.2. Financial outlook11.4.3. Product summary11.4.4. Recent developments
11.5. Medtronic
11.5.1. Company details11.5.2. Financial outlook11.5.3. Product summary11.5.4. Recent developments
11.6. Ypsomed
11.6.1. Company details11.6.2. Financial outlook11.6.3. Product summary11.6.4. Recent developments
11.7. Becton Dickinson
11.7.1. Company details11.7.2. Financial outlook11.7.3. Product summary11.7.4. Recent developments
11.8. Others
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment






Related Reports
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.